Intravenous Infusions Plc (GHSE:IIL)
Ghana · Delayed Price · Currency is GHS 0.5400
0.00 (0.00%)
At close: Sep 16, 2026
Intravenous Infusions Ratios and Metrics
Market cap in millions GHS. Fiscal year is January - December.
Millions GHS. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 148 | 14 | 14 | 14 | 11 | 14 | |
Market Cap Growth | 980.00% | 0% | 0% | 25.00% | -20.00% | 6.02% |
Enterprise Value | 157 | 21 | 24 | 28 | 27 | 25 |
Last Close Price | 0.54 | 0.05 | 0.05 | 0.05 | 0.04 | 0.05 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 5.40 | - | 11.97 |
PS Ratio | 22.75 | 1.48 | 0.55 | 0.44 | 0.54 | 0.61 |
PB Ratio | 9.11 | 1.22 | 0.86 | 0.79 | 0.74 | 0.75 |
P/TBV Ratio | 9.11 | 1.22 | 0.87 | 0.80 | 0.75 | 0.75 |
P/FCF Ratio | - | - | 2.45 | 5.75 | 24.26 | - |
P/OCF Ratio | - | - | 1.83 | 3.25 | 3.82 | 4.16 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 24.13 | 2.25 | 0.97 | 0.89 | 1.31 | 1.09 |
EV/EBITDA Ratio | - | - | 16.52 | 3.82 | - | 14.01 |
EV/EBIT Ratio | - | - | 29.70 | 4.29 | - | 20.14 |
EV/FCF Ratio | - | - | 4.34 | 11.72 | 58.71 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.57 | 0.87 | 0.55 | 0.76 | 1.09 | 0.90 |
Debt / EBITDA Ratio | - | - | 5.99 | 1.79 | - | 9.29 |
Debt / FCF Ratio | - | - | 1.57 | 5.50 | 35.65 | - |
Net Debt / Equity Ratio | 0.55 | 0.86 | 0.46 | 0.74 | 1.03 | 0.85 |
Net Debt / EBITDA Ratio | -1.89 | -1.32 | 4.98 | 1.76 | -5.74 | 8.83 |
Net Debt / FCF Ratio | -1.73 | -11.17 | 1.31 | 5.38 | 33.55 | -4.04 |
Asset Turnover | 0.16 | 0.22 | 0.55 | 0.67 | 0.44 | 0.54 |
Inventory Turnover | 0.84 | 1.51 | 2.17 | 2.19 | 1.62 | 1.76 |
Quick Ratio | 0.46 | 0.34 | 0.58 | 0.81 | 0.83 | 1.31 |
Current Ratio | 0.76 | 0.56 | 0.83 | 1.11 | 1.15 | 1.86 |
Return on Equity (ROE) | -27.55% | -34.07% | -3.87% | 15.85% | -21.22% | 6.33% |
Return on Assets (ROA) | -8.21% | -11.85% | 1.12% | 8.73% | -4.29% | 1.83% |
Return on Invested Capital (ROIC) | -20.88% | -35.96% | 3.06% | 15.79% | -10.05% | 3.13% |
Return on Capital Employed (ROCE) | -24.40% | -47.70% | 4.00% | 25.40% | -12.60% | 3.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -2.99% | -33.76% | -4.69% | 18.54% | -31.97% | 8.36% |
FCF Yield | -3.51% | -6.36% | 40.78% | 17.39% | 4.12% | -28.13% |
Dividend Yield | - | - | - | 5.90% | - | - |
Payout Ratio | - | - | - | - | - | 61.94% |
Total Shareholder Return | -17.87% | - | - | 5.90% | - | - |